MDACC Study No:2012-0377 ( NCT No: NCT01599949)
Title:A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy
Principal Investigator:Michael Wang
Treatment Agent:PCI-32765
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if ibrutinib can help
control MCL that has returned after treatment with bortezomib. The safety of
this drug will also be studied.

Ibrutinib is designed to block an enzyme (protein) that affects how certain
types of blood can cause cancer cells to grow and survive.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:PCI-32765
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Janssen Research & Development
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults